Try LifeScience Products:
AI-Powered
Pharmaceutical Intelligence
Access to drugs, clinical trials, patents, literatures and news in one search
Try:
AL-102 (Ayala)Crohn DiseasePneumococcal InfectionsFGFRL1APOC3Pfizer Inc.
90
K
Drugs & Biologics
46
K
Targets
986
K
Organizations
938
K
/
200
K
Clinical Trials / Results
66
M
Literatures
16
M
Patents
Recent blog posts
Virion Therapeutics Reports Promising Phase 1b Results for HBV Treatment at EASL Congress
Latest Hotspot
3 min read
Virion Therapeutics Reports Promising Phase 1b Results for HBV Treatment at EASL Congress
12 June 2024
Virion Therapeutics Announces Encouraging Phase 1b Immunogenicity Data of New HBV Treatment VRON-0200 at EASL Congress.
Read →
FDA Greenlights Phase II/III Trial of KPG-121 Coupled with Abiraterone for Initial Therapy in mCRPC
Latest Hotspot
3 min read
FDA Greenlights Phase II/III Trial of KPG-121 Coupled with Abiraterone for Initial Therapy in mCRPC
12 June 2024
Kangpu Biopharmaceuticals recently revealed that the U.S. Food and Drug Administration has granted approval for a Phase II/III clinical trial investigating KPG-121 in combination with Abiraterone.
Read →
AbbVie Begins Phase 3 Trial for ABBV-383 in Multiple Myeloma, Advancing Oncology Pipeline
Latest Hotspot
3 min read
AbbVie Begins Phase 3 Trial for ABBV-383 in Multiple Myeloma, Advancing Oncology Pipeline
12 June 2024
AbbVie has reported that the inaugural patient has received treatment with the experimental ABBV-383 in the CERVINO Phase 3 clinical trial.
Read →
Check out our latest report
Global Drug R&D Express (Apr 2024)

Global Drug R&D Express (Apr 2024)

This report compiles and summarizes the basic information of all the first-to-market and special review drugs globally for the month of March totaling 90 drugs. Among them, 2 first-to-market drugs and 2 drugs under special review were selected for detailed analysis. The report provides an in-depth interpretation of these drugs, covering various aspects such as basic information, development status, technological barriers, mechanism of action, clinical trials, and competitive landscape.

Global Drug R&D Express (Mar 2024)

Global Drug R&D Express (Mar 2024)

This report compiles and summarizes the basic information of all the first-to-market and special review drugs globally for the month of March totaling 93 drugs. Among them, 2 first-to-market drugs and 2 drugs under special review were selected for detailed analysis. The report provides an in-depth interpretation of these drugs, covering various aspects such as basic information, development status, technological barriers, mechanism of action, clinical trials, and competitive landscape.

Global Drug R&D Express (Feb 2024)

Global Drug R&D Express (Feb 2024)

This report compiles and summarizes the basic information of all the first-to-market and special review drugs globally for the month of December, totaling 59 drugs. Among them, 2 first-to-market drugs and 3 drugs under special review were selected for detailed analysis. The report provides an in-depth interpretation of these drugs, covering various aspects such as basic information, development status, technological barriers, mechanism of action, clinical trials, and competitive landscape.

Who We Serve
01
R&D Decision Makers
R&D Decision Makers
We provide R&D decision makers with access to accurate, connected data so they can quickly understand newly-emerged technology trends, have an insight into the competitive landscapes, uncover partnership opportunities, and decide the direction of innovation.
02
Business Development Professionals
Business Development Professionals
We provide 320,000+ life science organizations with drug pipeline and investment history, which help you make informed decisions on potential partnerships or acquisition targets.
03
Pharmaceutical Analyst
Pharmaceutical Analyst
We accelerate the research process for Pharmaceutical Analysts through various connected data, including drug approval, clinical trials, patent, non-patent literature and news. Synapse provides users with a 360-degree view of the competitive and technology landscape!
Get started for free today!
Access to drugs, clinical trials, patents, literatures and news in one search.